Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Serge Ferrari

Showing results (131-140 of 177) with videos related to

Pageof 18
Sort By:
JBMR Plus|November 11, 2021
Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment GoalsFelicia Cosman, Cesar Libanati, Cynthia Deignan, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 7, 2017
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its ExtensionSteven R Cummings, Serge Ferrari, Richard Eastell, et al.
Nutrients|October 27, 2022
A Novel Quantitative Computer-Assisted Score Can Improve Repeatability in the Estimate of Vascular Calcifications at the Abdominal AortaMaria Fusaro, Enrico Schileo, Gianluigi Crimi, et al.
The Journal of Clinical Endocrinology and Metabolism|May 19, 2023
Biochemical Markers of Bone Fragility in Patients With DiabetesChristian Meier, Richard Eastell, Dominique D Pierroz, et al.
Swiss Medical Weekly|September 6, 2017
Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCOChristian Meier, Brigitte Uebelhart, Bérengère Aubry-Rozier, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 20, 2021
Fracture Risk Following an Atypical Femoral FractureMarie-Josée Bégin, Marie-Claude Audet, Thierry Chevalley, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|February 15, 2022
Romosozumab and antiresorptive treatment: the importance of treatment sequenceFelicia Cosman, David L Kendler, Bente L Langdahl, et al.
BMC Musculoskeletal Disorders|April 29, 2017
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension studyJonathan D Adachi, Henry G Bone, Nadia S Daizadeh, et al.
Archives of Osteoporosis|July 31, 2025
Early transition from short-term romosozumab to antiresorptive therapies: analysis of 26 casesJudith Everts-Graber, Serge Ferrari, Albrecht Popp, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 22, 2011
Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humansAnna Rufo, Andrea Del Fattore, Mattia Capulli, et al.
Pageof 18

Showing results (131-140 of 177) with videos related to

Sort By:
Pageof 18
JBMR Plus|November 11, 2021
Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment GoalsFelicia Cosman, Cesar Libanati, Cynthia Deignan, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 7, 2017
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its ExtensionSteven R Cummings, Serge Ferrari, Richard Eastell, et al.
Nutrients|October 27, 2022
A Novel Quantitative Computer-Assisted Score Can Improve Repeatability in the Estimate of Vascular Calcifications at the Abdominal AortaMaria Fusaro, Enrico Schileo, Gianluigi Crimi, et al.
The Journal of Clinical Endocrinology and Metabolism|May 19, 2023
Biochemical Markers of Bone Fragility in Patients With DiabetesChristian Meier, Richard Eastell, Dominique D Pierroz, et al.
Swiss Medical Weekly|September 6, 2017
Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCOChristian Meier, Brigitte Uebelhart, Bérengère Aubry-Rozier, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 20, 2021
Fracture Risk Following an Atypical Femoral FractureMarie-Josée Bégin, Marie-Claude Audet, Thierry Chevalley, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|February 15, 2022
Romosozumab and antiresorptive treatment: the importance of treatment sequenceFelicia Cosman, David L Kendler, Bente L Langdahl, et al.
BMC Musculoskeletal Disorders|April 29, 2017
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension studyJonathan D Adachi, Henry G Bone, Nadia S Daizadeh, et al.
Archives of Osteoporosis|July 31, 2025
Early transition from short-term romosozumab to antiresorptive therapies: analysis of 26 casesJudith Everts-Graber, Serge Ferrari, Albrecht Popp, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 22, 2011
Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humansAnna Rufo, Andrea Del Fattore, Mattia Capulli, et al.
Pageof 18